跳至主要内容
临床试验/NCT00547495
NCT00547495已完成3 期

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Tadalafil Administered "On Demand" to Patients With Erectile Dysfunction

Eli Lilly and Company1 个研究点 分布在 1 个国家目标入组 343 人开始时间: 2004年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
343
试验地点
1
主要终点
Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in SEP diary

研究概览

简要总结

Study to determine how safe and effective tadalafil is for Japanese men taking it when they need to get and keep an erection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •3 months history of erectile dysfunction (ED)
  • •Anticipate a monogamous relationship with a female sexual partner
  • •Be able to make minimum required sexual intercourse attempts
  • •Abstain from using any other ED treatment

排除标准

  • •Other primary sexual disorders
  • •History of radical prostatectomy or other pelvic surgery that affected being able to have an erection
  • •History of penile implant or clinically significant penile deformity.
  • •Nitrate use
  • •Certain heart problems

研究组 & 干预措施

1

Placebo Comparator

Placebo tablet

干预措施: placebo (Drug)

4

Active Comparator

20 mg tadalafil

干预措施: tadalafil (Drug)

3

Active Comparator

10 mg tadalafil

干预措施: tadalafil (Drug)

2

Active Comparator

5 mg tadalafil

干预措施: tadalafil (Drug)

结局指标

主要结局

Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in SEP diary

时间窗: 12 weeks

次要结局

  • Change from baseline to endpoint of various questions from the IIEF and SEP diary(12 weeks)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验